Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 10/20 | 0.48 |
| ▸ | PLK3 | Q9H4B4 | 5/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | METAP2 | P50579 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | F2R | P25116 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16127894 | 0.90 | KMT2A (0.45) | PLK1PLK3GAAL3MBTL1KMT2A | |
| SCHEMBL16088691 | 0.87 | KMT2A (0.61) | PLK1PLK3GAAL3MBTL1METAP2 | |
| SCHEMBL16088649 | 0.83 | METAP2 (0.62) | PLK1PLK3METAP2 | |
| SCHEMBL16088632 | 0.82 | PLK1 (0.54) | PLK1PLK3GAAL3MBTL1METAP2 | |
| SCHEMBL17531732 | 0.82 | PLK1 (0.49) | PLK1PLK3GAAL3MBTL1METAP2 | |
| SCHEMBL16088725 | 0.81 | GAA (0.50) | PLK1GAAL3MBTL1KMT2AF2R | |
| SCHEMBL16088633 | 0.80 | PLK1 (0.54) | PLK1PLK3METAP2 | |
| SCHEMBL16088623 | 0.79 | F2R (0.53) | GAAL3MBTL1KMT2AF2RPPARA | |
| SCHEMBL16127834 | 0.78 | KMT2A (0.61) | GAAL3MBTL1KMT2APPARGPPARA | |
| SCHEMBL12172753 | 0.78 | KMT2A (0.67) | GAAL3MBTL1METAP2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452170-B2 | Compounds and methods for inducing chondrogenesis | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2016-09-27 | — | — | US | disclosed |
| US-20160045514-A1 | COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2016-02-18 | — | — | US | disclosed |
| US-20140271955-A1 | COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160045514-A1 | COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS | COL2A1, BMP4, COL1A1 | PLK1 1776/4885PLK3 3998/4885GAA 2935/4885 |
| US-20140271955-A1 | COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS | COL2A1, BMP4, COL1A1 | PLK1 1776/4885PLK3 3998/4885GAA 2935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.